Mostrar el registro sencillo del documento

Costo económico de las bacteriemias causadas por enterobacterias resistentes a carbapenémicos en una institución de Bogotá

dc.rights.licenseAtribución-NoComercial 4.0 Internacional
dc.contributor.advisorLeal Castro, Aura Lucia
dc.contributor.advisorAlvis Zakzuk, Nelson José
dc.contributor.authorBeltrán Toca, Lina María
dc.date.accessioned2020-12-09T17:23:38Z
dc.date.available2020-12-09T17:23:38Z
dc.date.issued2020-12-08
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/78690
dc.description.abstractBacterial infections with an antibiotical resistance profile are considered a worldwide public health problem. These infections are related to worse clinical outcomes, higher consumption of healthcare resources increasing the length of stays, absenteeism in the workplace and the economic burden that society and health system must bear. A retrospective cost of illness analysis was performed. By means of the technique of micro-costing, the frequencies of use of sanitary resources and the direct medical costs derived from the attention of bacteremia episodes by Enterobacteriaceae with carbapenemic resistance profile were estimated and compared. Additionally, a case-control design was used to estimate the factors associated with cost variation.
dc.description.abstractLas infecciones por bacterias con perfil de resistencia a antibióticos son consideradas como un problema de salud pública a nivel mundial. Estas infecciones están relacionadas con peores desenlaces clínicos, mayor consumo de recursos sanitarios, aumento de estancias hospitalarias, ausentismo laboral y una carga económica que la sociedad y el sistema de salud deben soportar. Se realizó un análisis de costo de enfermedad retrospectivo. Mediante la técnica de micro costeo, se estimaron y compararon las frecuencias de uso de recursos sanitarios y los costos directos médicos derivados de la atención de episodios de bacteriemia por Enterobacteriales con perfil de resistencia a carbapenémicos. Adicionalmente, se utilizó un diseño de casos y controles para estimar los factores asociados a la variación de los costos.
dc.format.extent139
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsDerechos reservados - Universidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.titleCosto económico de las bacteriemias causadas por enterobacterias resistentes a carbapenémicos en una institución de Bogotá
dc.typeOtro
dc.rights.spaAcceso abierto
dc.description.additionalLínea de investigación: Resistencia bacteriana con énfasis en microorganismos intrahospitalarios
dc.type.driverinfo:eu-repo/semantics/other
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Medicina - Maestría en Infecciones y Salud en el Trópico
dc.description.degreelevelMaestría
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.referencesAngles E. Uso racional de antimicrobianos y resistencia bacteriana ¿hacia dónde vamos? Rev Medica Hered. 2018;29(1):3.
dc.relation.referencesAlós J. Resistencia bacteriana a los antibióticos : una crisis global Antibiotic resistance : A global crisis. Enferm Infecc Microbiol Clin. 2015;33(10):692–9
dc.relation.referencesWHO. Global priority list of antibiotic-resistant batceria to guide research, discovery, and development of new antibiotics. Who [Internet]. 2017;7. Available from: https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
dc.relation.referencesSotomayor H, Burgos J, Arango M. Demostración de tuberculosis en una momia prehispanica colombiana por la ribotipificación del ADN de Mycobacterium tuberculosis. Biomédica [Internet]. 2004 [cited 2018 May 8];24:18–26. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572004000500004
dc.relation.referencesLemos E V. Impacto económico y clínico de la resistencia bacteriana a partir del análisis de Acinetobacter baumannii en unidades de cuidado intensivo de instituciones de tercer nivel de Bogotá. 2010.
dc.relation.referencesLemos E V., de la Hoz FP, Alvis N, Quevedo E, Einarson TR, Castañeda C, et al. Infectio : revista de la Asociación Colombiana de Infectología. Infectio [Internet]. 2013;17(4):185–92. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0123-93922013000400004
dc.relation.referencesBarrero LI, Castillo JS, Leal AL, Sánchez R, Cortés JA, Álvarez CA, et al. Impacto económico de la resistencia a meticilina en pacientes con bacteriemia por Staphylococcus aureus en hospitales de Bogotá. Biomédica [Internet]. 2014;34(3):345–53. Available from: http://www.revistabiomedica.org/index.php/biomedica/article/view/1692
dc.relation.referencesHernández-gómez C, Motoa G, Pallares C, Muñoz JS, Escandón-vargas K, Álvarez C, et al. Economic Impact of Carbapenemase-Producing Enterobacteriaceae Bloodstream Infection in Latin America. 2015;(October):10–1.
dc.relation.referencesVargas-Alzate CA, Higuita-Gutiérrez LF, Jiménez-Quiceno JN. Costos médicos directos de las infecciones del tracto urinario por bacilos Gram negativos resistentes a betalactámicos en un hospital de alta complejidad de Medellín, Colombia. Biomédica. 2019;39:35–49.
dc.relation.referencesAngeles-R. MC, Morales-J. AC, Yacarini-M. AE. Resistencia a los antibióticos: Agravamiento en la situación de salud pública. Rev del Cuerpo Médico del HNAAA. 2020;13(1):99–100.
dc.relation.referencesPérez DQ. Antimicrobial resistance: Evolution and current perspectives in the context of the “one health” approach. Rev Cubana Med Trop. 2017;69(3):1–17.
dc.relation.referencesWHO. Plan De Acción Mundial Sobre La Resistencia a Los Antimicrobianos. WHO Libr Cat Publ daata [Internet]. 2015; Available from: https://apps.who.int/iris/bitstream/handle/10665/255204/9789243509761-spa.pdf?ua=1
dc.relation.references(INS) IN de S. Circular 1000 - 0057. Fortalecimiento de las acciones de prevención, vigilancia y control de la emergencia y diseminacion de infecciones por Enterobacterias resistentes a carbapanémicos. 2012; Available from: http://www.ins.gov.co/normatividad/Normatividad/circular 0057 de 2012.PDF
dc.relation.referencesInstituto Nacional de Salud (INS). Resultados del Programa de Vigilancia por Laboratorio de Resistencia antimicrobiana en Infecciones Asociadas a la Atención en Salud ( IAAS ) 2016. 2016.
dc.relation.referencesCastillo JS, Leal AL, Alvarez CA, Cortés JA, Henríquez DE, Buitrago G, et al. Bacteriemia por Staphylococcus aureus resistente a la meticilina en la unidad de cuidados intensivos: revisión de los estudios de pronóstico. Infectio [Internet]. 2011;15(1):25–32. Available from: http://www.sciencedirect.com/science/article/pii/S012393921170073X
dc.relation.referencesMinisterio de Salud y Protección Social. PLAN NACIONAL DE RESPUESTA A LA RESISTENCIA A ANTIMICROBIANOS. 2018
dc.relation.referencesJanet Hindler MA, Humphries RM, Schuetz A, Professor D. CLSI AST News Update. 2020.
dc.relation.referencesAdeolu M, Alnajar S, Naushad S, Gupta RS. Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: Proposal for enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morgane. Int J Syst Evol Microbiol. 2016;66(12):5575–99.
dc.relation.referencesJanda JM. The Prokaryotes. In: Dworkin M, Falkow S, Rosenberg E, Schleifer K-H, Stackebrandt E, editors. The Prokaryotes [Internet]. Tercera ed. Springer; 2006. p. 5–40. Available from: http://www.springerlink.com/index/10.1007/0-387-30741-9
dc.relation.referencesFam N, Opin C, Comm J, Iii JJF, Control D, Diseases D, et al. Enterobacteriaceae. 2015
dc.relation.referencesPatel AK, Singhania RR, Pandey A, Joshi VK, Nigam PS, Soccol CR. Enterobacteriaceae, Coliforms and E.Coli: Introduction. Encycl Food Microbiol Second Ed. 2014;1:659–66.
dc.relation.referencesChurch LWP. Enterobacteriaceae. Clin Infect Dis Second Ed. 2015;888–94.
dc.relation.referencesDelcour AH. Outer Membrane Permeability and Antibiotic Resistance. Biochim Biophys Acta [Internet]. 2009;1794(5):808–16. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696358/pdf/nihms114274.pdf
dc.relation.referencesVinogradov E, Frirdich E, MacLean LL, Perry MB, Petersen BO, Duus JØ, et al. Structures of lipopolysaccharides from Klebsiella pneumoniae. Eluicidation of the structure of the linkage region between core and polysaccharide O chain and identification of the residues at the non-reducing termini of the O chains. J Biol Chem [Internet]. 2002 Jul 12 [cited 2018 Apr 23];277(28):25070–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11986326
dc.relation.referencesFarfán-garcía AE, Ariza-rojas SC, Andrea F, Lizeth V, Farfán-garcía AE. Mecanismos de virulencia de Escherichia coli enteropatógena. Rev Chil Infecto. 2016;33(4):438–50.
dc.relation.referencesTindall BJ, Sutton G, Garrity GM. Enterobacter aerogenes hormaeche and Edwards 1960 (Approved lists 1980) and Klebsiella mobilis bascomb et al. 1971 (approved lists 1980) share the same nomenclatural type (ATCC 13048) on the approved lists and are homotypic synonyms, with consequences for. Int J Syst Evol Microbiol. 2017;67(2):502–4
dc.relation.referencesNom AL, Opin C, Comm J, Grimont PAD, Grimont F, Entérobactéries U, et al. Enterobacter. Bergey’sManual Syst Archaea Bact Online. 2015;
dc.relation.referencesPaterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006;34(5 SUPPL.):20–8.
dc.relation.referencesNordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Vol. 20, Clinical Microbiology and Infection. 2014.
dc.relation.referencesIslas-Muñoz B, Volkow-Fernández P, Ibanes-Gutiérrez C, Villamar-Ramírez A, Vilar-Compte D, Cornejo-Juárez P. Bloodstream infections in cancer patients. Risk factors associated with mortality. Int J Infect Dis [Internet]. 2018 Jun 1 [cited 2018 Aug 5];71:59–64. Available from: https://www-sciencedirect-com.ezproxy.unal.edu.co/science/article/pii/S120197121830081X
dc.relation.referencesVillegas MV, Jiménez A, Esparza G, Appel TM. Carbapenemase-producing Enterobacteriaceae: A diagnostic, epidemiological and therapeutic challenge. Infectio. 2019;23(4):388–98.
dc.relation.referencesYi-Wei Tang, Stratton CW. Advanced techniques in diagnostic microbiology [Internet]. 2006. 550 p. Available from: https://link.springer.com/content/pdf/10.1007%2F0-387-32892-0.pdf
dc.relation.referencesGarcía MA, Iglesias JCF, Rotaeche AA, Sánchez MS. Bacteriemia, sepsis y shock séptico. Med - Programa Form Médica Contin Acreditado [Internet]. 2018 Apr [cited 2019 Apr 7];12(52):3066–75. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0304541218300623
dc.relation.referencesAkova M. Epidemiology of antimicrobial resistance in bloodstream infections. Virulence. 2016;7(3):252–66.
dc.relation.referencesDe La Rosa G, León AL, Jaimes F. Epidemiología y pronóstico de pacientes con infección del torrente sanguíneo en 10 hospitales de Colombia. Rev Chil infectología [Internet]. 2016;33(2):141–9. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182016000200003&lng=en&nrm=iso&tlng=en
dc.relation.referencesTham J. Extended-Spectrum Beta-Lactamase- Producing Enterobacteriaceae : Epidemiology , Risk Factors , and Duration of Carriage. 2012;0–85.
dc.relation.referencesDrawz SM, Bonomo RA. Three decades of ??-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.
dc.relation.referencesJeon JH, Lee JH, Lee JJ, Park KS, Karim AM, Lee CR, et al. Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance. Vol. 16, International Journal of Molecular Sciences. 2015.
dc.relation.referencesMeletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21.
dc.relation.referencesCodjoe F, Donkor E. Carbapenem Resistance: A Review. Med Sci. 2017;6(1):1.
dc.relation.referencesBedenić B, Plečko V, Sardelić S, Uzunović S, Godič Torkar K. Carbapenemases in gram-negative bacteria: Laboratory detection and clinical significance. Biomed Res Int. 2014;2014.
dc.relation.referencesRao S. Carbapenemases. Microrao. 2012. p. 1–12.
dc.relation.referencesSilveira MC, Azevedo da Silva R, Faria da Mota F, Catanho M, Jardim R, R Guimarães AC, et al. Systematic Identification and Classification of β-Lactamases Based on Sequence Similarity Criteria: β-Lactamase Annotation. Evol Bioinforma. 2018;14.
dc.relation.referencesRao M, Chandrashaker P, Mahale R, Shivappa S, Gowda R, Chitharagi V. Detection of carbapenemase production in Enterobacteriaceae and Pseudomonas species by carbapenemase Nordmannn - Poirel test. J Lab Physicians. 2019;11(2):107–10.
dc.relation.referencesLeal AL, Bocanegra R, Mojica IL, Cely JL. Manual de tomas de muestras para el análisis microbiologico. Secr Dist Salud Bogotá, DC. 2015;21.
dc.relation.referencesHrabák J, Chudáčková E, Papagiannitsis CC. Detection of carbapenemases in Enterobacteriaceae: A challenge for diagnostic microbiological laboratories. Clin Microbiol Infect. 2014;20(9):839–53.
dc.relation.referencesThe Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing CLSI supplement M100S. Clinical and Laboratory Standards Institute, Wayne, PA. 2016. 256 p.
dc.relation.referencesSahu C, Jain V, Mishra P, Prasad K. Clinical and laboratory standars institute versus European committee for antimicrobial susceptibility testing guidelines for interpretation of carbapenem antimicrobial susceptibility results for Escherichia coli in urinary tract infection (UTI). J Lab Physicians. 2018;10(3):289–93.
dc.relation.referencesNordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V, et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect [Internet]. 2012;18(5):432–8. Available from: http://dx.doi.org/10.1111/j.1469-0691.2012.03815.x
dc.relation.referencesNordmann P, Poirel L. Strategies for identification of carbapenemase-producing enterobacteriaceae. J Antimicrob Chemother. 2013;68(3).
dc.relation.referencesPark C-E. Clinical Laboratory Aspect of Carbapenem-Resistant Enterobacteriaceae . Korean J Clin Lab Sci. 2020;52(1):18–27.
dc.relation.referencesIovleva A, Doi Y. Carbapenem-Resistant Enterobacteriaceae. Clin Lab Med [Internet]. 2017;37(2):303–15. Available from: http://dx.doi.org/10.1016/j.cll.2017.01.005
dc.relation.referencesKost K, Yi J, Rogers B, Jerris R. Comparison of clinical methods for detecting carbapenem-resistant Enterobacteriaceae. Pract Lab Med [Internet]. 2017;8(October 2016):18–25. Available from: http://dx.doi.org/10.1016/j.plabm.2017.03.002
dc.relation.referencesGarcia S. Resistencia Y Métodos Fenotípicos De Detección Carbapenemases . Resistance Mechanisms and Phenotypic Methods for Detection. 2018;
dc.relation.referencesTrepanier P, Mallard K, Meunier D, Pike R, Brown D, Ashby JP, et al. Carbapenemase-producing Enterobacteriaceae in the UK: A national study (EuSCAPE-UK) on prevalence, incidence, laboratory detection methods and infection control measures. J Antimicrob Chemother. 2017;72(2):596–603.
dc.relation.referencesMediavilla- C, Valverde-troya M, Microbiología L De, Microbiología UGC De, Infecciosas E, Hospital P. Original breve Evaluación de un ensayo inmunocromatográfico para la detección de carbapenemasa OXA-48. 2017;30(1):45–9.
dc.relation.referencesHofko M, Mischnik A, Kaase M, Zimmermann S, Dalpke AH. Detection of carbapenemases by real-time PCR and melt curve analysis on the BD Max system. J Clin Microbiol. 2014;52(5):1701–4.
dc.relation.referencesGhebremedhin B, Halstenbach A, Smiljanic M, Kaase M, Ahmad-Nejad P. MALDI-TOF MS based carbapenemase detection from culture isolates and from positive blood culture vials. Ann Clin Microbiol Antimicrob. 2016;15(1):1–6.
dc.relation.referencesGarcía P, Allende F, Legarraga P, Huilcaman M, Solari S. Identificación bacteriana basada en el espectro de masas de proteínas: Una nueva mirada a la microbiología del siglo XXI. Rev Chil infectología [Internet]. 2012 Jun [cited 2018 Apr 24];29(3):263–72. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182012000300003&lng=en&nrm=iso&tlng=en
dc.relation.referencesBilozor A, Balode A, Chakhunashvili G, Chumachenko T, Egorova S, Ivanova M, et al. Application of Molecular Methods for Carbapenemase Detection. Front Microbiol. 2019;10(August):1–7.
dc.relation.referencesGarcía-Betancur JC, Appel TM, Esparza G, Gales AC, Levy-Hara G, Cornistein W, et al. Update on the epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther [Internet]. 2020;0(0). Available from: https://doi.org/10.1080/14787210.2020.1813023
dc.relation.referencesGutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–34.
dc.relation.referencesRodríguez-Baño J, Cisneros JM, Gudiol C, Martínez JA. Treatment of infections caused by carbapenemase-producing Enterobacteriaceae. Enferm Infecc Microbiol Clin [Internet]. 2014;32(S4):49–55. Available from: http://dx.doi.org/10.1016/S0213-005X(14)70174-0
dc.relation.referencesDaikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–8.
dc.relation.referencesTumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–43.
dc.relation.referencesBulik CC, Nicolau DP. Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(6):3002–4.
dc.relation.referencesKaraiskos I, Antoniadou A, Giamarellou H. Combination therapy for extensively-drug resistant gram-negative bacteria. Expert Rev Anti Infect Ther [Internet]. 2017;15(12):1123–40. Available from: https://doi.org/10.1080/14787210.2017.1410434
dc.relation.referencesNi W, Han Y, Liu J, Wei C, Zhao J, Cui J, et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: A systematic review and meta-analysis. Med (United States). 2016;95(11):1–10.
dc.relation.referencesCui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm [Internet]. 2019;41(6):1408–13. Available from: https://doi.org/10.1007/s11096-019-00912-5
dc.relation.referencesTumbarello M, Losito AR, Giamarellou H. Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections. Curr Opin Infect Dis. 2018;31(6):566–77.
dc.relation.referencesRodriguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-. Clin Microbiol Rev. 2018;31(2):1–42.
dc.relation.referencesAl-Ghoul WM, Kim MS, Fazal N, Azim AC, Ali A, Amulic B, et al. cr ipt ce pt us cr ipt Ac ce pt us. J Leukoc Biol [Internet]. 2015;13(3):1–10. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1044532315000147%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/15715589%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/19467703%5Cnhttp://ac.els-cdn.com/S0143400409001313/1-s2.0-S0143400409001313-main.pdf?_tid=499806ed760fd88be79
dc.relation.referencesMcKinnell J, Connolly L, Pushkin R, Jubb A, O´Keeffe B, Serio A, et al. Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study. 2017;4(Suppl 1):348–9.
dc.relation.referencesCloutier D, Komirenko A, Cebrik D, Keepers T, Krause K, Connolly L, et al. Plazomicin Vs. Meropenem for Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Diagnosis-specific Results From the Phase 3 EPIC Study. Vol. 4. 2017.
dc.relation.referencesBonomo RA, Bonomo RA. Clinical Infectious Diseases Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens. Available from: https://ecdc.
dc.relation.referencesChew KL, Tay MKL, Cheng B, Lin RTP, Octavia S. Aztreonam - avibactam combinatio restores susceptibility of aztreonam in dual carbapenemase producing Enterobacteriaceae. 2018;62(8):1–3.
dc.relation.referencesKattan R, Liddawi R, Ghneim R, Siryani I, Al-dawodi R, Abu-diab A, et al. Emergence of Klebsiella pneumoniae Carbapenemase ( bla KPC-2 ) in members of the Enterobacteriaceae family in Palestine. 2012;2(2):1–9.
dc.relation.referencesLogan LK, Weinstein RA. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis. 2017;215(Suppl 1):S28–36.
dc.relation.referencesMunoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis [Internet]. 2013;13(9):785–96. Available from: http://dx.doi.org/10.1016/S1473-3099(13)70190-7
dc.relation.referencesOcampo AM, Vargas CA, Sierra PM, Cienfuegos AV, Jiménez JN. Caracterización molecular de un brote de Klebsiella pneumoniae resistente a carbapenémicos en un hospital de alto nivel de complejidad de Medellín, Colombia. Biomédica [Internet]. 2015;35(4):496–504. Available from: http://www.revistabiomedica.org/index.php/biomedica/article/view/2610
dc.relation.referencesLucía M, Martínez O, Enrique M, Duran M, Vigilancia D, Del Riesgo En A, et al. Protocolo de vigilancia en salud pública infecciones asociadas a dispositivos. Inst Nac Salud [Internet]. 2016;1–65. Available from: http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/sivigila/Protocolos SIVIGILA/PRO Infecciones asociadas a dispositivos.pdf
dc.relation.referencesEsparza G. Bacterias Gram negativas resistentes a carbapenemicos en Colombia: a desafio continuo al sistema de salud.
dc.relation.referencesINS. Informe De Resultados De La Vigilancia Por Laboratorio De Resistencia Antimicrobiana En Infecciones Asociadas a La Atención En Salud (Iaas) 2018 Dirección. Epidemiol las Infecc Asoc a la atención en salud. 2019;29–44.
dc.relation.referencesSegel JE. Cost-of-Illness Studies — A Primer. Diabetes [Internet]. 2006;(January):1–39. Available from: http://www.rti.org/pubs/coi_primer.pdf
dc.relation.referencesJo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol [Internet]. 2014 Dec [cited 2018 Apr 24];20(4):327. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25548737
dc.relation.referencesMejia Mejia A, Viscaya MM. Evaluación económica para la toma de decisiones en salud en Colombia. Políticas en salud Monit estrátegico [Internet]. 2014;(5):70–5. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/SSA/Articulo 9.pdf
dc.relation.referencesTarricone R. Cost-of-illness analysis. What room in health economics? Health Policy (New York). 2006;77(1):51–63.
dc.relation.referencesAndronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: An audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess (Rockv). 2009;13(29).
dc.relation.referencesGandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect [Internet]. 2014;20(10):973–80. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1198743X14653635
dc.relation.referencesMejía,Carlos. Villatoro,Guillermo. Silvestre,Mónica. de Britz,Hilda. Valle, Rosa. Remei M. Costo del tratamiento de infecciones nosocomiales por gérmenes multirresistentes, Hospital Roosevelt. Rev Panam Infectol [Internet]. 2008;10(4):96–100. Available from: http://www.revistaapi.com/wp-content/uploads/2014/03/mat-14.pdf
dc.relation.referencesHuebner C, Roggelin M, Flessa S. Economic burden of multidrug-resistant bacteria in nursing homes in Germany: a cost analysis based on empirical data. BMJ Open [Internet]. 2016;6(2):e008458. Available from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2015-008458
dc.relation.referencesChandy SJ, Naik GS, Balaji V, Jeyaseelan V, Thomas K, Lundborg CS. High cost burden and health consequences of antibiotic resistance: The price to pay. J Infect Dev Ctries. 2014;8(9):1096–102.
dc.relation.referencesEvans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance*. Crit Care Med [Internet]. 2007;35(1):89–95. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003246-200701000-00015
dc.relation.referencesNg E, Earnest A, Lye DC, Ling ML, Ding Y, Hsu LY. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals. Ann Acad Med Singapore. 2012;41(5):189–93.
dc.relation.referencesMacvane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum ??-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9(4):232–8.
dc.relation.referencesEsteve-Palau E, Solande G, Sánchez F, Sorlí L, Montero M, Güerri R, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study. J Infect [Internet]. 2015 Dec 1 [cited 2018 Apr 23];71(6):667–74. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0163445315002662
dc.relation.referencesMaslikowska JA, Walker SAN, Elligsen M, Mittmann N, Palmay L, Daneman N, et al. Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. J Hosp Infect [Internet]. 2016 Jan [cited 2018 Apr 23];92(1):33–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26597637
dc.relation.referencesDaroukh A, Delaunay C, Bigot S, Ceci JM, Siddhoun N, Bukreyeva I, et al. Characteristics and costs of carbapenemase-producing enterobacteria carriers (2012/2013). Med Mal Infect [Internet]. 2014;44(7):321–6. Available from: http://dx.doi.org/10.1016/j.medmal.2014.06.004
dc.relation.referencesOtter JA, Burgess P, Davies F, Mookerjee S, Singleton J, Gilchrist M, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017;23(3):188–96.
dc.relation.referencesMeng X, Liu S, Duan J, Huang X, Zhou P, Xiong X, et al. Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital. BMC Infect Dis [Internet]. 2017;17(1):82. Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-2176-9
dc.relation.referencesNdir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, et al. Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae: Clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar, Senegal. Antimicrob Resist Infect Control [Internet]. 2016;5(1):1–8. Available from: http://dx.doi.org/10.1186/s13756-016-0114-7
dc.relation.referencesThaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8(4):403–16.
dc.relation.referencesBartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect [Internet]. 2017;23(1):48.e9-48.e16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27642178%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5547745
dc.relation.referencesDrummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015.
dc.relation.referencesCorporación Hospitalaria Juan Ciudad – Méderi , Colombia Gloria Pulido Moya La Corporación Hospitalaria Juan Ciudad - Méderi.
dc.relation.referencesMoreno Viscaya M, Mejía Mejía A, Castro Jaramillo HE. Manual para la elaboración de evaluaciones económicas en salud. Instituto de Evaluación Tecnológia en Salud. 2014.
dc.relation.referencesMinisterio de Salud y Protección Social. Listado de precios promedio y unidades en la cadena de comercialización de medicamentos 2018. (Modificado) [Internet]. 2018. Available from: https://web.sispro.gov.co/WebPublico/Consultas/ConsultarCNPMCadenaComercializacionCircu2yPA_028_2_1.aspx
dc.relation.referencesFondo Nacional de Estupefacientes. Precio medicamentos de estupefacientes. 2018.
dc.relation.referencesMinisterio de Salud y Protección Social. Base de datos de medicamentos con precio regulado o con precio de referencia [Internet]. 2018. Available from: https://www.minsalud.gov.co/salud/MT/Paginas/medicamentos-regulacion-precios.aspx
dc.relation.referencesPresidencia de la República. Acuerdo No. 256 DE 2001 Por el cual se aprueba el “Manual de Tarifas” de la Entidad Promotora de Salud del Seguro Social EPS-ISS. Vol. 001. 2001. p. 1–213.
dc.relation.referencesAlvis-Zakzuk NJ, Díaz-Jiménez D, Castillo-Rodríguez L, Castañeda-Orjuela C, Paternina-Caicedo Á, Pinzón-Redondo H, et al. Economic Costs of Chikungunya Virus in Colombia. Value Heal Reg Issues. 2018;17(51):32–7.
dc.relation.referencesOrtiz-Mayorga JL, Pineda-Rodríguez IG, Dennis RJ, Porras A. Costos atribuidos a las infecciones asociadas con la atención en salud en un hospital de Colombia, 2011-2015. Biomédica [Internet]. 2019;39(1):102–12. Available from: https://www.revistabiomedica.org/index.php/biomedica/article/view/4061
dc.relation.referencesGonzalez M del R. Manual de estadistica no parametrica con STATA y STATISTICA. 2000.
dc.relation.referencesMinisterio de Salud. Resolución No. 8430 de 1993. Norma científica, técnicas y administrativas para la investigación en salud. 1993;
dc.relation.referencesColombia C de la R de. Ley Estaturatia 1581 del 2012. Ámbito De Aplicación. 2018;2012(Octubre 17):1–32.
dc.relation.referencesGarcés D, Barragán FJ. Ronda clínica y epidemiológica. Introducción al análisis multivariable (parte II). Iatreia. 2014;28(1):87–96.
dc.relation.referencesCastellanos-olivares A, Rojas-peñaloza DJ, Vásquez-márquez DPI. O Causalidad En Medicina ? 2016;232–6.
dc.relation.referencesBerea-Baltierra R, Rivas-Ruiz R, Pérez-Rodríguez M, Palacios-Cruz L, Moreno J, Talavera JO. Clinical research XX. From clinical judgment to multiple logistic regression model. Rev Med Inst Mex Seguro Soc. 2014;52(2):192–7.
dc.relation.referencesMartinez HC. Impacto economico de la colonizacion nasal por Staphylococcus aureus Meticilino Resistente (SAMR), en pacientes que ingresan al Servicio de Cirugia Cardiovascular del Hospital Universitario San Ignacio (HUSI), de la ciudad de Bogota. 2015
dc.relation.referencesHuang W, Qiao F, Zhang Y, Huang J, Deng Y, Li J, et al. In-hospital Medical Costs of Infections Caused by Carbapenem-resistant Klebsiella pneumoniae. Clin Infect Dis. 2018;67(December 2017):S225–30.
dc.relation.referencesThaden J, Li Y, Ruffin F, Maskarenic S, Hill-Rorie JM, Wanda L, et al. Increased cost with multidrug resistant gram Negative bloodstream infections are primarily due to patients with hospital acquired infections. Antimicrob Agents Chemoterapy. 2016;(December):1–27.
dc.relation.referencesJudd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. Am J Infect Control [Internet]. 2016;44(11):1275–9. Available from: http://dx.doi.org/10.1016/j.ajic.2016.04.218
dc.relation.referencesUlu kılıc ayşegül. Economic burden of multidrug resistant gram negative infections in a developing country. Erciyes Med J. 2019;41(3):2017–20.
dc.relation.referencesSegagni Lusignani L, Presterl E, Zatorska B, Van den Nest M, Diab-Elschahawi M. Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011-2016) case-control study. Antimicrob Resist Infect Control [Internet]. 2020 Jan 17;9:18. Available from: https://pubmed.ncbi.nlm.nih.gov/31988746
dc.relation.referencesSt JH. Code sepsis initiatives. In: American Journal of Nursing. 2018. p. 130.
dc.relation.referencesSunny T, Jacob R, K K, Varghese S. Self-medication: Is a serious challenge to control antibiotic resistance? Natl J Physiol Pharm Pharmacol. 2019;9(0):1.
dc.relation.referencesManyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications. Molecules [Internet]. 2018 Mar 30;23(4):795. Available from: https://pubmed.ncbi.nlm.nih.gov/29601469
dc.relation.referencesServices U. D of H and H. Antibiotic resistance threats in the United States. Centers Dis Control Prev [Internet]. 2019;1–113. Available from: https://www.cdc.gov/drugresistance/biggest_threats.html
dc.relation.referencesJaime Cerda L. Glosario de términos utilizados en evaluación económica de la salud. Rev Med Chil [Internet]. 2010 Sep [cited 2020 Oct 9];138(SUPPL. 2):76–8. Available from: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872010001000003&lng=es&nrm=iso&tlng=es
dc.relation.referencesGrau S. Principales variables que determinan el coste económico en el tratamiento de una infección. Enferm Infecc Microbiol Clin [Internet]. 2017;35(Supl 1):41–5. Available from: http://dx.doi.org/10.1016/S0213-005X(17)30035-6
dc.relation.referencesMauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54(1):109–15.
dc.relation.referencesMariappan S, Sekar U, Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes. Int J Appl basic Med Res [Internet]. 2017;7Mariappan(1):32–9. Available from: https://pubmed.ncbi.nlm.nih.gov/28251105
dc.relation.referencesGualtero S, Valderrama S, Valencia M, Rueda D, Muñoz-Velandia O, Ariza B, et al. Factors associated with mortality in Infections caused by Carbapenem-resistant Enterobacteriaceae. J Infect Dev Ctries. 2020;14(6):654–9.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.proposalCost of illness
dc.subject.proposalCostos de la enfermedad
dc.subject.proposalDrug resistance
dc.subject.proposalResistencia a antibióticos
dc.subject.proposalBacteremia
dc.subject.proposalBacteriemias
dc.subject.proposalEnterobacteriaceae resistente a carbapenémicos
dc.subject.proposalCarbapenem - resistant Enterobacteriaceae
dc.type.coarhttp://purl.org/coar/resource_type/c_1843
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2


Archivos en el documento

Thumbnail
Nombre:
1019068120.2020.pdf
Tamaño:
1.673Mb
Formato:
PDF
Descargar
Thumbnail
Nombre:
license_rdf
Tamaño:
701bytes
Formato:
application/rdf+xml
Descargar

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Atribución-NoComercial 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito